6
6 Three quarters (74%) of DAAs-experienced patients achieved an SVR with 12 weeks of SOF + PEG/RBV therapy despite multiple resistance variants and prior courses of therapy The presence of baseline RAVs against any or all 3 non structural proteins (NS3, NS5a, NS5b) did not impact overall SVR The 12-week SOF + PEG/RBV regimen was safe and well tolerated Sofosbuvir-containing regimens are effective in these patients with no other currently approved alternatives Pol, S. et al. EASL 2014, Abstract #O55

12
12 Retreatment with an extended duration of SOF + RBV to 24 weeks or the addition of IFN to a 12 week regimen resulted in high SVR rates in GT 2 and GT 3 patients who previously failed SOF+RBV-containing regimens The 12-week regimen containing IFN had higher overall rates of SVR and was more effective in patients with cirrhosis The 24-week IFN-free regimen was safe and well tolerated and offers a retreatment option for those ineligible to receive IFN Esteban, R. et al. EASL 2014, Abstract #O8

59
59 First dedicated trial of IFN-free regimen in cirrhotic patients, including patients often ineligible for clinical trials (low platelets, low albumin, radiographic ascites) SVR rates of 92% to 96% with 12 and 24 weeks of treatment, with high SVR rates in all subgroups analyzed 12 or 24 weeks of treatment were similarly well tolerated, with low rates of treatment discontinuation Efficacy and safety in this large cirrhotic population is similar to non-cirrhotics treated with the same regimen